SyntheticMRs software solution SyMRI receives regulatory approval in Brazil

July 08, 2020
SyntheticMR announced today that their quantitative imaging software solution SyMRI has received regulatory approval in Brazil and can now be sold on this market.

“We are ecstatic to bring our SyMRI software to the Brazilian market,” says Kyle Frye, President SyntheticMR Inc. “We know there are many healthcare providers that are excited to utilize our technology to speed up their current workflow and add additional information to aid in upfront diagnosis. To be able to sell within Brazil opens up abundant opportunities for SyntheticMR Inc. It also means that combined with our previous regulatory clearance in Mexico we now have access to some of the largest markets in the Americas.”

SyMRI provides multiple contrast weighted images and quantitative information about the patient in a single 5-6 minute scan, enabling users to speed up their imaging workflow and add objective decision support to their practice.

SyntheticMR AB develops and markets innovative software solutions for Magnetic Resonance Imaging (MRI). SyntheticMR AB’s product SyMRI® delivers multiple contrast images and quantitative data from a single 6-minute scan. The product is available in different packages. SyMRI IMAGE supports faster MRI workflows and improved patient throughput. SyMRI NEURO delivers automatic segmentation of brain tissue, supporting objective decision support. SyMRI is CE-marked and FDA 510(k) cleared. SyMRI is a registered trademark in Europe and in the USA. SyntheticMR is listed on the Spotlight Stock Market in Stockholm, Sweden.